Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29219024 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL30134660 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18245634 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18246012 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18531483 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL30134665 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18247139 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18247127 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18531539 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL18531538 | 0.95 | APLNR (1.00) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | claimed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | claimed |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. | 2024-11-07 | — | — | US | disclosed |
| US-20240252493-A1 | Apelin Receptor Modulators for Treating Age-Related Muscle Conditions | BioAge Labs, Inc. | 2024-08-01 | — | — | US | disclosed |
| WO-2024148104-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240122926-A1 | APELIN RECEPTOR MODULATORS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. | 2024-04-18 | — | — | US | disclosed |
| CN-117897157-A | Apelin receptor modulators for the treatment of age-related muscle disorders | 百爱及生物医药公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024072907-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4319873-A1 | APELIN RECEPTOR MODULATORS FOR TREATING AGE-RELATED MUSCLE CONDITIONS | Bioage Labs, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240041878-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | BioAge Labs, Inc. | 2024-02-08 | — | — | US | disclosed |
| WO-2023235360-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | BioAge Labs, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | APLNR, GLP1R, GIPR | APLNR 1/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | APLNR 296/4885 |
| US-20240122926-A1 | APELIN RECEPTOR MODULATORS FOR TREATING MUSCLE CONDITIONS | APLNR, AGER, GPR35 | APLNR 1/4885 |
| US-20240252493-A1 | Apelin Receptor Modulators for Treating Age-Related Muscle Conditions | APLNR, AGER, GPR35 | APLNR 1/4885 |
| US-20240041878-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | APLNR, GPR180, GPR142 | APLNR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.